Qiagen Board Approves €9.7B EQT Bid, Puts Show Uncertainty
Qiagen's board unanimously approved a €9.7B EQT acquisition at €46.50/share, but the stock closed at $50.22, below the offer equivalent. December put options are trading with elevated implied volatili
EQT's €9.7B QIAGEN Bid: Options Market Prices Uncertainty
NEW YORK, November 1 —
Qiagen N.V. (QGEN) has received unanimous board acceptance of an EQT XI consortium offer worth €9.7 billion, yet the December 18 $55 Put carried some of the highest implied volatility of any equity option in the market as of October 31, a strike 6% above the deal's dollar equivalent pricing a scenario the headline won't acknowledge.
- EQT XI acquiring Qiagen at €46.50/share (~$52 USD), €9.7bn total; formal tender not yet launched.
- QGEN closed at $50.22, above the $49.02 analyst consensus price target but below the ~$52 USD offer equivalent.
- The December 18 $55 Put ranked among the market's highest implied-volatility equity options as of October 31.
Below the Ask, Above the Consensus
At $50.22, QGEN sits inside the offer spread but not at its limit. Qiagen, which sells molecular-diagnostic tools including its QuantiFERON-TB tuberculosis assay, HPV genotyping kits, and quantitative PCR instruments to clinical labs and research institutions worldwide, delivered four consecutive earnings beats and carries a 66.4% gross margin. Trailing revenue of $2.10 billion grew only 0.3%, a rate that makes take-private logic clear: this is a cash-flow story, not a growth story. EQT, competing in a diagnostics market alongside Roche, Abbott Laboratories, and Thermo Fisher Scientific, is paying for the margin and the installed base.
$55 Knows What the Announcement Doesn't
The formal tender bid for QGEN shares had not yet commenced as of late October, a procedural gap the options market appears to be pricing directly. That Put, already in the money, carries elevated implied volatility that charges a premium for protection against a sharp retracement if the bid lapses. Guidance has been suspended in connection with the deal, removing the quarterly anchors that might otherwise keep the stock from falling hard. A 90-day gain of 21.3% makes the downside scenario specific: the ground gained since deal speculation began is the ground at risk.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| QGEN | $10.4B | 19.2x | +9.9% |
| TECH | $11.4B | 31.4x | +18.6% |
| BIO | $10.0B | 38.2x | +19.5% |
| CRL | $17.2B | 28.2x | +100.9% |
| MYGN | $607M | n/a | -22.4% |
| QDEL | $909M | 9.3x | -52.2% |
Deal Math Is the Only Math That Matters Now
Whether December 18 arrives with a completed tender or a broken bid is the only question that matters for QGEN at current prices. The stock's 1-year return of 7.98% shows the pre-deal reality: Qiagen was growing earnings but not revenue, with top-line growth of just 0.3% over twelve months. Upside above ~$52 requires EQT to raise its offer; downside arrives the moment the bid faces any complication. Neutral is the honest position: the business case is intact, but new buyers are paying for a deal, not a company. Run the free Qiagen N.V. deep-dive →
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
What is the EQT offer for Qiagen?
EQT XI consortium is offering €46.50/share, approximately $52 USD, valuing the total deal at €9.7 billion. The bid has received unanimous board approval, although a formal tender had not yet commenced as of late October.
Why is the stock trading below the deal price?
QGEN closed at $50.22, above the $49.02 analyst consensus but below the ~$52 USD offer equivalent. The stock sits within the offer spread as the market prices in uncertainty about whether the deal will close.
What does Qiagen sell?
Qiagen sells molecular-diagnostic tools including its QuantiFERON-TB tuberculosis assay, HPV genotyping kits, and quantitative PCR instruments to clinical labs and research institutions worldwide.
Why do December put options show such high volatility?
The December 18 $55 put option carried some of the highest implied volatility of any equity option in the market as of October 31, pricing protection against a sharp retracement if the bid lapses. Guidance has been suspended in connection with the deal, removing quarterly anchors that might otherwise constrain downside moves.
Why is EQT paying €9.7 billion for Qiagen?
EQT is paying for Qiagen's strong 66.4% gross margin and installed base, not growth. Although the company delivered four consecutive earnings beats, trailing revenue grew only 0.3% over twelve months, making this a cash-flow acquisition story rather than a growth story.
EQT's all-cash bid to take Qiagen private at €46.50 per share has cleared the board and is described as nearing close — yet the December 18 $55 Put on QGEN carried some of the highest implied volatility of any equity option in the market as of October 31, suggesting that at least part of the options market is pricing in meaningful deal uncertainty even as headlines signal a done deal.